We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 6/1/2021

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now


Journal Scan / Research · April 14, 2021

Efficacy and Safety of Dapagliflozin in People With HFrEF

JAMA Cardiology




This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Cardiology
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
JAMA Cardiol 2021 Mar 31;[EPub Ahead of Print], JH Butt, KF Docherty, MC Petrie, M Schou, MN Kosiborod, E O'Meara, T Katova, CEA Ljungman, M Diez, MO Ogunniyi, AM Langkilde, M Sjöstrand, D Lindholm, O Bengtsson, FA Martinez, P Ponikowski, MS Sabatine, SD Solomon, PS Jhund, JJV McMurray, L Køber

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading